![conference banner](/images/conference-banner.jpeg)
Abstract
Despite an extraordinary investment in R the yield of successful new drugs has been disproportionately low in recent years, suggesting that the whole process of drug development requires rethinking and reform. Most analyses on this issue focus on molecular target discovery considerations. Target identification is characterized by a surplus of potential targets, but there is a translational bottleneck primarily due to limitations of currently employed target validation platforms. Meanwhile, the clinical entities, to which treatments are directed, are also highly complex in terms of pathophysiologic mechanisms and manifestations. In the present study we discuss the limitations of current molecular target discovery approaches mainly in regard to selectivity and efficacy. We also describe the constraints imposed on drug development by the current diagnostic constructs and the tendency towards dissecting the complex clinical phenotypes to component intermediate phenotypes. Finally, we describe how the reconsideration of molecular and clinical targets in polygenic diseases may lead to new strategies of pharmacological intervention directed against component dysfunctions, rather than the whole complex phenotype. Such strategies involve the combination of single ligands that act selectively on multiple molecules involved in a particular disease, or the employment of “multi-targeted” drugs, i.e. single drug molecules that hit selectively multiple receptors sharing common binding sites.
Keywords: Systemic evaluation of ligands by exponential enrichment, High throughput screening, Acute respiratory distress syndrome, Multiple organ distress syndrome, Extracellular signal-regulated kinase, Human genome program
Current Topics in Medicinal Chemistry
Title: Rethinking Target Discovery in Polygenic Diseases
Volume: 6 Issue: 16
Author(s): Christodoulos S. Flordellis, Antonis S. Manolis, Herve Paris and Andreas Karabinis
Affiliation:
Keywords: Systemic evaluation of ligands by exponential enrichment, High throughput screening, Acute respiratory distress syndrome, Multiple organ distress syndrome, Extracellular signal-regulated kinase, Human genome program
Abstract: Despite an extraordinary investment in R the yield of successful new drugs has been disproportionately low in recent years, suggesting that the whole process of drug development requires rethinking and reform. Most analyses on this issue focus on molecular target discovery considerations. Target identification is characterized by a surplus of potential targets, but there is a translational bottleneck primarily due to limitations of currently employed target validation platforms. Meanwhile, the clinical entities, to which treatments are directed, are also highly complex in terms of pathophysiologic mechanisms and manifestations. In the present study we discuss the limitations of current molecular target discovery approaches mainly in regard to selectivity and efficacy. We also describe the constraints imposed on drug development by the current diagnostic constructs and the tendency towards dissecting the complex clinical phenotypes to component intermediate phenotypes. Finally, we describe how the reconsideration of molecular and clinical targets in polygenic diseases may lead to new strategies of pharmacological intervention directed against component dysfunctions, rather than the whole complex phenotype. Such strategies involve the combination of single ligands that act selectively on multiple molecules involved in a particular disease, or the employment of “multi-targeted” drugs, i.e. single drug molecules that hit selectively multiple receptors sharing common binding sites.
Export Options
About this article
Cite this article as:
Flordellis S. Christodoulos, Manolis S. Antonis, Paris Herve and Karabinis Andreas, Rethinking Target Discovery in Polygenic Diseases, Current Topics in Medicinal Chemistry 2006; 6 (16) . https://dx.doi.org/10.2174/156802606778194226
DOI https://dx.doi.org/10.2174/156802606778194226 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
Call for Papers in Thematic Issues
Adaptogens—History and Future Perspectives
Adaptogens are pharmacologically active compounds or plant extracts that are associated with the ability to enhance the body’s stability against stress. The intake of adaptogens is associated not only with a better ability to adapt to stress and maintain or normalise metabolic functions but also with better mental and physical ...read more
AlphaFold in Medicinal Chemistry: Opportunities and Challenges
AlphaFold, a groundbreaking AI tool for protein structure prediction, is revolutionizing drug discovery. Its near-atomic accuracy unlocks new avenues for designing targeted drugs and performing efficient virtual screening. However, AlphaFold's static predictions lack the dynamic nature of proteins, crucial for understanding drug action. This is especially true for multi-domain proteins, ...read more
Artificial intelligence for Natural Products Discovery and Development
Our approach involves using computational methods to predict the potential therapeutic benefits of natural products by considering factors such as drug structure, targets, and interactions. We also employ multitarget analysis to understand the role of drug targets in disease pathways. We advocate for the use of artificial intelligence in predicting ...read more
Chemistry Based on Natural Products for Therapeutic Purposes
The development of new pharmaceuticals for a wide range of medical conditions has long relied on the identification of promising natural products (NPs). There are over sixty percent of cancer, infectious illness, and CNS disease medications that include an NP pharmacophore, according to the Food and Drug Administration. Since NP ...read more
![Wayfinder Image](/images/wayfinder.jpg)
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The Prothrombotic State in Hypertension and the Effects of Antihypertensive Treatment
Current Pharmaceutical Design Peptide modules for overcoming barriers of nucleic acids transport to cells
Current Topics in Medicinal Chemistry Cardiovascular Effects of Modulators of Soluble Guanylyl Cyclase Activity
Cardiovascular & Hematological Agents in Medicinal Chemistry Molecular Basis of Cardioprotection by Erythropoietin
Current Molecular Pharmacology Na+/Ca2+ Exchange Inhibitors: A New Class of Calcium Regulators
Cardiovascular & Hematological Disorders-Drug Targets Future Contrast Agents for Molecular Imaging in Stroke
Current Medicinal Chemistry Inflammation in Atherosclerosis: A New Therapeutic Target
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents Curcumin Nanomicelle Improves Lipid Profile, Stress Oxidative Factors and Inflammatory Markers in Patients Undergoing Coronary Elective Angioplasty; A Randomized Clinical Trial
Endocrine, Metabolic & Immune Disorders - Drug Targets Cardioprotective Effects of Serca2a Overexpression Against Ischemiareperfusion- induced Injuries in Rats
Current Gene Therapy Carbon Monoxide and Iron Modulate Plasmatic Coagulation in Alzheimer’s disease
Current Neurovascular Research Prediction of Degeneration of Native and Bioprosthetic Aortic Valves:Issue-Related Particularities of Diabetes Mellitus
Infectious Disorders - Drug Targets Novel Therapeutic Targets for Acute Pancreatitis and Associated Multiple Organ Dysfunction Syndrome
Current Drug Targets - Inflammation & Allergy Drug Delivery Systems for the Treatment of Diabetes Mellitus: State of the Art
Current Pharmaceutical Design Memantine: Its Role in Vascular Dementia
Drug Design Reviews - Online (Discontinued) Recent Advances and Patents on Coronary Sinus Perfusion Devices for Treatment of Heart Disease
Recent Patents on Biomedical Engineering (Discontinued) Treating and Preventing No Reflow in the Cardiac Catheterization Laboratory
Current Cardiology Reviews Vitamin D/VDR, Probiotics, and Gastrointestinal Diseases
Current Medicinal Chemistry Editorial [Hot Topic Intracellular Calcium Signaling: Holding the Balance between Health and Disease Guest Editor: Luca Munaron]
Current Medicinal Chemistry Cysteinyl Leukotrienes (CysLTs): Role in Obesity-Induced Asthma
Current Molecular Medicine Nanocapsulated Ascorbic Acid in Combating Cerebral Ischemia Reperfusion- Induced Oxidative Injury in Rat Brain
Current Alzheimer Research